Compare
Lagevrio vs. Paxlovid

Lagevrio (molnupiravir) is an antiviral medication that was given Emergency Use Authorization (EUA) by the FDA in December 2021 to treat people with mild-to-moderate COVID-19. It's a capsule that's taken by mouth and a full course of treatment only lasts 5 days. Most people don't have many side effects with Lagevrio (molnupiravir). But possible side effects include diarrhea, nausea, and dizziness. Lastly, this medication doesn't have any known medication interactions.

• Mild-to-moderate COVID-19 in adults who are at high risk for severe illness and aren't able to receive other FDA-authorized treatments

• Diarrhea (2%)

• Birth defects
• Bone and cartilage damage
• Risk of serious allergic reaction

Paxlovid (nirmatrelvir / ritonavir) is an antiviral used to treat mild-to-moderate coronavirus SARS-CoV-2 (COVID-19) in people who are at high risk for severe illness. It's taken by mouth twice daily for 5 days. Some common side effects include changes in taste and diarrhea. Paxlovid (nirmatrelvir / ritonavir) can interact with other medications, like blood thinners or certain blood pressure medications, so your healthcare team will review your medication list before you start treatment. This medication is likely safe to take during pregnancy, but more research is needed in this area.

Note: Paxlovid (nirmatrelvir / ritonavir) Paxlovid (nirmatrelvir / ritonavir) is fully FDA-approved to treat COVID-19 in adults. But it's still under emergency use authorization (EUA) for children ages 12-18 years old.

• Mild-to-moderate COVID-19 in people ages 12 years and older (and weighing over 88 lbs) who are at high risk for severe illness

• Changes in taste (6%)
• Diarrhea (3%)

• Serious interactions with other medications
• Severe allergic reaction
• Liver problems
• Risk of resistance to certain HIV medications